市場調查報告書
商品編碼
1403327
靜脈血栓栓塞治療市場:按設備、庫存、應用、最終用戶劃分 - 全球預測(~2030 年)Venous Thromboembolism Treatment Market by Device (Thrombectomy, Inferior Vena Cava Filter [Retrievable, Permanent], Stockings, Compression Pump) Application (DVT, Pulmonary Embolism) End User (Hospital, Ambulatory Care Center) - Global Forecast to 2030 |
預計2030年全球靜脈血栓栓塞治療市場規模將達44億美元,2023年至2030年複合年增長率為7.2%。
在對市場狀況進行廣泛的初級和二級研究以及深入分析後,本報告深入了解靜脈血栓栓塞治療市場的關鍵驅動因素、限制、挑戰和機會。
靜脈血栓栓塞的高發生率、癌症發生率的上升、糖尿病和肥胖等繼發性危險因子的盛行率不斷增加、骨科手術數量的增加以及對微創治療手術的需求不斷增加,是推動靜脈血栓成長的關鍵因素。血栓栓塞治療市場。此外,治療方案的可用性和可負擔性的提高、VTE診斷和治療方法的進步以及新興國家的市場擴張預計將為市場成長創造機會。
然而,產品缺陷和產品召回的情況可能會抑制市場成長。此外,缺乏對靜脈血栓栓塞的認識以及對壓縮衣副作用的認識不斷增強是市場成長的主要挑戰。
在本報告涵蓋的設備中,血栓切除設備預計將在 2023 年佔據靜脈血栓栓塞治療市場的最大份額。該細分市場的巨大市場份額是由於心血管疾病的盛行率不斷上升、對微創手術的日益偏好以及新型血栓切除設備的推出。
在本報告涵蓋的應用中,深部靜脈血栓領域預計將在2023年佔據靜脈血栓栓塞治療市場的最大份額。此細分市場的巨大市場份額是由於肥胖症盛行率不斷上升、老年人口不斷增加、生活方式相關疾病導致的深部靜脈栓塞病例不斷增加、過度飲酒以及對 DVT 的認識不斷提高。
在本報告涵蓋的最終用戶中,醫院部門預計將在 2023 年佔據靜脈血栓栓塞治療市場的最大份額。這一巨大的市場份額歸因於靜脈血栓栓塞的盛行率不斷上升、醫院和診所數量不斷增加、高技能專業人員的存在以及醫院的高購買力。前往醫院的便利性以及大量患者在同一地點尋求全面醫療保健服務(包括診斷、治療和手術)也有助於該細分市場佔據巨大的市場份額。
全球靜脈血栓栓塞治療市場區域狀況的詳細分析為五個關鍵區域提供了詳細的定性和定量見解:北美(美國、加拿大)、歐洲(德國、法國、亞太地區(中國、日本、印度)、拉丁美洲以及中東/非洲其他地區。
預計到2023年,北美將佔據全球靜脈血栓栓塞治療市場的最大份額,其次是歐洲、亞太地區、拉丁美洲以及中東和非洲。然而,亞太地區預計在預測期內複合年增長率最高。該區域市場的成長是由慢性病盛行率上升、久坐生活方式的人數增加、醫療保健成本增加、政府旨在改善醫療基礎設施的支持措施以及靜脈血栓栓塞等因素所推動的。這被認為是由於以下因素造成的例如提高對該問題的認識。
Venous Thromboembolism Treatment Market by Device (Thrombectomy, Inferior Vena Cava Filter [Retrievable, Permanent], Stockings, Compression Pump) Application (DVT, Pulmonary Embolism) End User (Hospital, Ambulatory Care Center) - Global Forecast to 2030.
The global venous thromboembolism treatment market is projected to reach $4.40 billion by 2030, at a CAGR of 7.2% from 2023 to 2030.
After conducting an extensive primary and secondary study and an in-depth analysis of the market scenario, this report offers insights into the key drivers, constraints, challenges, and opportunities within the venous thromboembolism treatment market.
The high prevalence of venous thromboembolism, rising incidence of cancer, growing prevalence of secondary risk factors such as diabetes and obesity, increase in orthopedic surgical procedures, and the rising demand for minimally invasive treatment procedures are the key factors driving the growth of the venous thromboembolism treatment market. Furthermore, the growing accessibility and affordability of treatment options, advancements in VTE diagnosis and treatment methods, and the market expansion in emerging economies are expected to create market growth opportunities.
However, instances of product failure and product recalls may restrain the market's growth. Additionally, lack of awareness about venous thromboembolism and increasing awareness of probable side effects of compression garments are major challenges for market growth.
Among the devices covered in this report, in 2023, the thrombectomy devices segment is expected to account for the largest share of the venous thromboembolism treatment market. The large market share of this segment is attributed to the increasing prevalence of cardiovascular diseases, growing preference for minimally invasive procedures, and launches of new thrombectomy devices.
Among the applications covered in this report, in 2023, the deep vein thrombosis segment is expected to account for the largest share of the venous thromboembolism treatment market. The large market share of this segment is attributed to the increasing prevalence of obesity, a growing geriatric population, rising cases of deep vein thrombosis due to lifestyle-related diseases, excessive alcohol consumption, and heightened awareness of DVT.
Among the end users covered in this report, in 2023, the hospitals segment is expected to account for the largest share of the venous thromboembolism treatment market. The large market share is attributed to the increasing prevalence of venous thromboembolism, the rising number of hospitals and clinics, the presence of highly skilled professionals, and the high purchasing power of hospitals. The easy accessibility to hospitals, coupled with a large patient population seeking comprehensive healthcare services, including diagnosis, treatment, and surgeries at a single location, also contributes to the significant market share of this segment.
An in-depth analysis of the geographical scenario of the global venous thromboembolism treatment market provides detailed qualitative and quantitative insights into the five major geographies: North America (U.S., Canada), Europe (Germany, France, U.K., Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India), Latin America, and the Middle East & Africa.
In 2023, North America is expected to account for the largest share of the global venous thromboembolism treatment market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. However, Asia-Pacific is slated to register the largest CAGR during the forecast period. The growth of this regional market can be attributed to factors such as the growing prevalence of chronic diseases, the increasing number of people living sedentary lifestyles, growing health expenditures, supportive government initiatives aimed at improving healthcare infrastructure, and rising awareness regarding venous thromboembolism.
The key players operating in the global venous thromboembolism treatment market are ALN Implants chirurgicaux (ALN Surgical Implants) (France), AngioDynamics, Inc. (U.S.), Argon Medical Devices, Inc. (U.S.), ArjoHuntleigh AB (Sweden), Boston Scientific Corporation (U.S.), Cardinal Health, Inc. (U.S.), Cook Group Incorporated (U.S.), Koninklijke Philips N.V. (Netherlands), DS MAREF Co., LTD (South Korea), Enovis Corporation (U.S.), LifeTech Scientific Corporation (China), Medtronic plc (Ireland), and Stryker Corporation (U.S.).
Venous Thromboembolism Treatment Market Assessment-by Device
Note: Other devices & accessories include extraction and repositioning devices for vena cava filters and garments for compression therapy (excluding stockings).
Venous Thromboembolism Treatment Market Assessment-by Application
Venous Thromboembolism Treatment Market Assessment-by End User
Note: Other end users include nursing care centers, long-term care centers, and military health centers.
Venous Thromboembolism Treatment Market Assessment-by Geography